Accumulating evidence of possible benefit warrants randomized trials, experts say ...

Five-year overall survival (OS) for patients with de novo metastatic cancer increased from 10.6% in 1976-1981 to 23.6% in 2015-2020, representing more than a twofold improvement. Survival gains were ...

Megan Sweet slices tumors. A normal day in the lab finds the Virginia Tech graduate student with hands deep inside a refrigerated metal box, pulling a mounted mouse-grown tumor incrementally closer to ...

GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...

GLP-1 drugs may be linked to a lower risk of cancer progression, according to new research that will be presented next week ...

Cancer cell DNA doubling — when cells accidentally duplicate all chromosomes without dividing — now has a new risk factor: ...

GLP-1 drugs, such as Ozempic and Wegovy, may slow down the spread of obesity-related cancers, according to researchers ...

NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American ...

GT Biopharma Inc. GTBP on Thursday dosed the first patient on a Phase 1 dose-escalation basket trial evaluating GTB-5550, its ...

An innovative blood test could detect hidden signs of cancer spreading earlier than CT scans and help adjust treatments in a timely manner.